{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"4.0","value":"4.0"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"3.5","value":"2.8"},{"groupId":"OG002","lowerLimit":"9.4","upperLimit":"9.4","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"TTR was defined, for participants with an objective response (confirmed CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which was subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \\<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.","dispersionType":"Full Range","groups":[{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all participants who received at least one dose of study drug and who had confirmed CR or PR. Participants were classified according to study treatment actually received. If participant received more than one treatment, participant was classified according to first treatment received. Here 'number of participants analyzed' signifies participants evaluable for this outcome measure with at least 1 confirmed complete response or partial response.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until first documentation of CR or PR (maximum up to 7.3 years)","title":"TTR for Combination C","type":"SECONDARY","unitOfMeasure":"Months"}